

OCCURRENCE AND ANTIMICROBIAL SUSCEPTIBILITY PROFILE OF VANCOMYCIN RESISTANCE AMONG CLINICAL ISOLATES OF *STAPHYLOCOCCUS AUREUS* IN ENUGU METROPOLIS, NIGERIA

ABSTRACT

Introduction: *Staphylococcus aureus* is a significant cause of community-acquired and healthcare-acquired infections worldwide. Methicillin-resistant *Staphylococcus aureus* infections have been treated with vancomycin, a last-resort antibiotic. This study aimed to investigate the occurrence of vancomycin resistance among *Staphylococcus aureus* isolates obtained from different clinical samples. **Material and Methods:** The study was conducted from February to August 2022 in the Microbiology Laboratory of the University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu. A total of 150 *Staphylococcus aureus* isolates from different clinical samples were used for the study. The antimicrobial susceptibility profile was done using the Kirby-Bauer disc diffusion procedure. Methicillin resistance was detected using the cefoxitin disc diffusion technique. VRSA was confirmed using the broth dilution method. **Results:** Isolates showed high resistance to cephalosporins; 100% resistance to cefixime, to cefotaxime 98.7%, to cefuroxime 93.3%, and to ceftriaxone 80%. There was also high resistance of isolates to imipenem 98.7%, Augmentin 92.2%, erythromycin, and azithromycin 81.3% and 80.0% respectively. Of the 150 isolates, 51(34.0%) were methicillin-sensitive *Staphylococcus aureus* (MSSA) and 99(66.0%) were MRSA. Of the 99 MRSA strains, 9 (9.1%) were vancomycin-resistant (VRSA), 24 (24.2%) were vancomycin intermediate (VISA) and 66 (66.7%) were vancomycin-sensitive (VSSA). The overall prevalence of VRSA was 6%. **Conclusion:** The isolates had a high resistance to the antibiotics used in our study. The proportion of MRSA was high. A high percentage of VRSA/VISA was also detected. To prevent the further spread of VRSA, rigorous monitoring of vancomycin treatment, response, and the development of appropriate control guidelines are strongly recommended and required.

KEYWORDS: Antimicrobial Resistance, *Staphylococcus aureus*, MRSA, VRSA

1. INTRODUCTION

Staphylococcus aureus is a significant pathogen found across hospital-acquired and community-acquired infections and causes numerous infectious diseases including mild skin and soft tissue infections, osteomyelitis, joint infections, cardiovascular diseases, infectious endocarditis, bacteremia, life-threatening pneumonia in both apparent individuals and those with underlying diseases. [1,2]. It is an endogenous microbe that colonizes the skin, nose, anus, intestine, and vulva [3]. The rising incidence of

both community and nosocomial staphylococcal infections overlap with the advent of multidrug-resistant *S. aureus*, making antibiotic therapies impotent [4].

S. aureus has lately acquired resistance to a spectrum of antibiotics, particularly the beta-lactam group [5]. The development of methicillin-resistant *S. aureus* (MRSA) and vancomycin-resistant *S. aureus* (VRSA) is a major international health problem. Presently, VRSA and MRSA isolates are regarded as highly powerful and harmful agents that may have the capacity to cause severe damage globally in the absence of suitable alternatives [6].

Methicillin-resistant *S. aureus* (MRSA) is a strain of *S. aureus* that has failed to respond to earlier generations of penicillin (oxacillin, methicillin, dicloxacillin, cloxacillin, and nafcillin) antimicrobial drugs. The resistance is mediated by the conjugated staphylococcal cassette chromosome mec (SCCmec) gene. All these SCCmec have the *mecA* gene, which encodes the low-affinity penicillin-binding protein 2a [7].

S. aureus uses a variety of resistance mechanisms, including the development of beta-lactamase enzymes to render beta-lactam antibiotics ineffective, an efflux pump for thrusting out drugs like tetracyclines[8], synthesis of aminoglycosides modifying enzymes to deactivate aminoglycoside antibiotics, modifications of DNA gyrase and topoisomerase IV expression of fluoroquinolone antibiotics. These expressions of Mec genes alter penicillin-binding proteins [9] and decrease the accumulation of macrolides antibiotics [7, 10].

In the late 1980s, vancomycin became the preferred antibiotic for treating patients infected with MRSA in hospitals. [11] Nevertheless, after several years on the market, vancomycin-resistant *S. aureus* strains evolved in Japan. VRSA strains emerged in the United States five years after that in Japan [12]. *S. aureus* acquires vancomycin resistance plasmid gene from vancomycin-resistant Enterococcus (VRE) via transposon Tn1546 [7, 13]. Two types of glycopeptide-resistant *S. aureus* emerged as a result of increased use of vancomycin [4]. The vancomycin-intermediate *S. aureus* (VISA) which is one, is associated with a cell wall that is thicker and weakly cross-linked, leading to the formation of targets at the cell margin that sequesters glycopeptides. The second type is vancomycin-resistant *S. aureus* (VRSA), which causes high-level resistance [14]. As the infections caused by VRSA increase yearly, there is growing evidence that they will become more common over time [15, 16]. *S. aureus* heteroresistance to vancomycin has been reported, which could contribute to the generation of more resistant strains in the future. The global prevalence of VRSA ranges from 9.8% to 52.4% [7, 17, 18]. Resistance was mostly recorded among patients from intensive care units, followed by those from medical wards and then surgery[5]. Patients with bacteremia and/or endocarditis are more likely to die from VRSA infections; hence a treatment plan that has high bactericidal performance must be evaluated while considering therapy options. VRSA has adverse consequences for patients due to *S. aureus*' aggressive features. In addition to the aggressiveness of *S. aureus* and the limited options for therapy in MRSA infections, the emergence of VRSA constitutes a significant threat to the general public. Moreover, the likelihood of these microbes spreading within patients is disturbing [14].

In Nigeria, multi-drug resistance infection has continued to rise due to numerous causes such as abuse of drugs, indigence, self-medication, and a shortage of trained medical personnel. As the global community faces the continuing growth in antimicrobial resistance, enough statistics regarding AMR must be available; this might serve as the essential framework for establishing successful measures for managing the issue of antimicrobial resistance [1].

However, data are scarce on susceptibility patterns for *S. aureus*, particularly MRSA and VRSA, in our research region. Even worse, there has been no appropriate regulation of medications, and self-administration of antibiotics is common, contributing to antibiotic resistance in the research area. Periodic and increased surveillance of antibiotic susceptibility of bacterial isolates from various clinical sources is required. Hence, this study aimed to determine the susceptibility profile of *S. aureus*, and the occurrence of MRSA, VRSA, and VISA among the isolates in the Enugu metropolis [3].

2. MATERIALS AND METHODS

2.1 Study design

A descriptive-comparative study conducted from February to August 2022 in the Microbiology Laboratory of the University of Nigeria Teaching Hospital, Ituku-Ozalla. The study was approved by the Ethics Committee of University of Nigeria Teaching Hospital Ituku-Ozalla Enugu.

2.2 Study Area

Enugu Metropolis is in Enugu State, Nigeria's South-East geopolitical zone. It is bordered by the states of Ebony to the east, Abia to the south, Kogi and Benue to the north, and Anambra to the west. It is located at the foot of the Udi Plateau. Enugu State has three senatorial zones: Enugu North, Enugu East, and Enugu West with seventeen local government areas. There are four referral hospitals within the metropolis and many private hospitals.

2.3 Laboratory Examinations

Collection of Isolates and Identification

A total of 150 laboratory-confirmed *S. aureus* isolates were randomly collected from a variety of clinical specimens, including blood, urine, wounds, semen, high-vaginal swab (HVS), Endocervical smear (ECS), Urethral smear (US) and catheter tips. *S. aureus* colonies were collected aseptically using a sterile wire loop and subcultured onto nutrient agar slants before being incubated at 37°C for 24 hours. They were sub-cultured again onto mannitol salt agar and blood agar (Oxoid, UK). The plates were incubated at 37°C for 24 hrs. Following incubation, colonies with yellowish pigments from the agar were characterized using standard microbiological procedures such as Gram stain, catalase test, and coagulase test [19, 20].

2.4 Antimicrobial Susceptibility Test

Antimicrobial susceptibility was determined using the Kirby-Bauer disc diffusion method by Clinical and Laboratory Standard Institute (CLSI) standards [21]. The antimicrobial susceptibility profile of each isolated *S. aureus* was assessed using the conventional disc diffusion method on Mueller-Hinton agar and aerobically incubated at 37°C for 18-24 hours; The following antibiotics were included Cefuroxime (30µg), Cefotaxime (25µg), Ceftriaxone (45µg), Augmentin (30µg), Cefixime (5µg), Cefoxitin (30µg), Erythromycin (15µg), Gentamicin (1µg), Ciprofloxacin (5µg), Ofloxacin (5µg), Imipenem (10µg), Levofloxacin (5µg), Azithromycin (5µg), Vancomycin (30µg).

2.5 The Detection of Methicillin Resistance

Methicillin resistance was established using the disc diffusion susceptibility test. This was accomplished using Cefoxitin 30µg antibiotics disc (Oxoid, UK) on Mueller-Hinton agar plate and interpreted according to CLSI recommendations. The growth of *S. aureus* with a zone of inhibition surrounding cefoxitin disc \leq 21mm was classified as methicillin-resistant *S. aureus*, while isolates with a zone of inhibition \geq 22mm were characterized as methicillin-susceptible *S. aureus* (MSSA) [22].

2.6 The determination of minimum inhibitory concentration (MIC) of vancomycin

The minimal inhibitory concentration (MIC) was determined for VISA and VRSA. The MIC of vancomycin for MRSA was measured using the broth dilution method employed by Anosike et al. [23]. One gram of vancomycin powder in a bottle was dissolved in 20 ml of sterile water to yield a vancomycin concentration of 50 mg/ml according to the manufacturer's guidelines. 1 ml of 50 mg/ml vancomycin was diluted with 50 ml of water to get 1 mg/ml (1000 µg/ml) of vancomycin. This was then treated to a two-fold serial dilution in test tubes using sterile nutrient broth. Vancomycin concentrations were graded as follows: 0.98µg/ml, 1.95µg/ml, 3.9µg/ml, 7.8µg/ml, 15.63µg/ml, 31.25µg/ml, 62.5µg/ml, 125µg/ml, 250µg/ml, 500µg/ml, and 1000 µg/ml. The inoculums were prepared using 0.5 McFarland as standard. Three control culture tubes were also included: one with sterile nutrient broth, one with the test organism, and one with vancomycin (1000 µg/ml) exclusively. All were labeled appropriately. After 24 hours of incubation, all test tubes were inspected for evidence of growth. Turbidity in the test tubes after incubation indicated bacterial growth. The absence of turbidity in the test tube showed that growth was inhibited. The MIC was the lowest concentration of vancomycin that inhibited the growth of the test organism. In the controls, growth was observed in the test tube containing nutrient broth and the test organism alone. Evidence of growth was not seen in the tubes containing sterile nutrient broth alone, and nutritional broth with vancomycin

antibiotic alone. Vancomycin MIC values of $< 2 \mu\text{g/ml}$ were considered susceptible, ≥ 4 to $8 \mu\text{g/ml}$ were intermediate resistant, and $\geq 16 \mu\text{g/ml}$ were resistant [22].

3. RESULTS

Fig 1 shows the distribution of clinical isolates of *Staphylococcus aureus* according to the source of the isolates. The highest number of isolates was recovered from urine 78 (52.0%), followed by HVS 18 (12.0%), ECS 14 (9.3%), urethral smear 12 (8.0%), and the least was from catheter tips 2 (1.3%).

Fig 2 shows the antimicrobial susceptibility profile of the total isolates. Isolates showed high resistance to cephalosporins; 100% resistance to cefixime, 98.7% to cefotaxime, 93.3% to cefuroxime, and 80% to ceftriaxone. There was also high resistance of isolates to carbapenem; imipenem at 98.7%, Augmentin at 92.2%, and macrolides; erythromycin and azithromycin at 81.3% and 80.0% respectively.

Fig 3 shows the results of Cefoxitin susceptibility. Of the 150 clinical isolates of *S. aureus*, 99 (66.0%) were methicillin-resistant (MRSA) and 51 (34.0%) were methicillin-sensitive (MSSA).

Table 1 shows the prevalence of MRSA and MSSA according to the source of the isolate. Out of the 99 samples that were MRSA, isolates from catheter tip ranked highest at 2 (100%), followed by HVS 14 (77.8%), ECS 10 (71.4%), and the least blood culture 2 (33.3%). Of the 52 isolates that were MSSA, urine isolates ranked highest 4 (66.7%).

Table 2 shows the MIC results of MRSA isolates in the graded concentration of vancomycin. There was no growth in the tubes of 66.7% (66/99) of MRSA isolates with concentrations of 0.98-500 $\mu\text{g/ml}$, 9.1% (9/99) showed evidence of growth from 0.98-7.8 $\mu\text{g/ml}$, 24.2% (24/99) showed evidence of growth in all the tubes except positive control.

Table 3 shows the distribution of Vancomycin sensitive (VSSA), Vancomycin intermediate VISA, and Vancomycin-resistant (VRSA) isolates according to the source of the isolates. Of the 99 isolates that were MRSA, 9.1% (9/99) were VRSA, 17.2% (17/99) were VISA, and 66.7% (66/9) were VSSA. The highest occurrence of VRSA was seen in the urethral swab 16.7% (1/6) followed by wound swabs 14.7% (1/7) and the least was in the urine 12.9% (7/54). There was no VRSA in isolates from catheter tips, blood culture, semen, HVS, and ECS.




Fig1: Distribution of Clinical Isolates of *Staphylococcus aureus* according to Isolate Source




Fig 2: Resistant and Susceptibility Profiles of Clinical Isolates of *Staphylococcus aureus*




Fig 3: Distribution of Methicillin Resistance and Methicillin sensitive isolates of S. aureus

Table 1: Distribution of MRSA and MSSA according to isolate source

Sample Source	MRSA: No/%	MSSA: No/%	Total
Blood Culture	2 (33.3)	4 (66.7)	6 (4.0)
Urethral smear	6 (50.0)	6 (50.0)	12 (8.0)
Urine	54 (69.2)	24 (30.8)	78 (52.0)
Semen	4 (66.7)	2 (33.3)	6 (4.0)
High Vaginal Swab(HVS)	14 (77.8)	4 (22.2)	18 (12.0)
Endocervical Swab (ECS)	10 (71.4)	4 (28.6)	14 (9.3)
Catheter Tip	2 (100)	0 (0.0)	2 (1.3)
Wound	7 (50.0)	7 (50.0)	14 (9.3)
Total	99 (66.0)	52 (34.7)	150 (100.0)
P= 0.290	X²= 8.51		

Table 2: MIC of Vancomycin for MRSA Isolates

Concentration (µg/ml)	No/%	Result
0.98-500	66(66.7)	No growth
0.98-7.8	24 (24.2)	Turbid
0.98-500	9 (9.1)	Turbid

Table 3: Distribution of MRSA Isolates according to Vancomycin Susceptibility

Sample Source	MRSA: No/%	VRSA*: No/%	VISA*:No/%	VSSA*: No/%
Blood Culture	2	0 (0.0)	0 (0.0)	2 (100)
Urethral Swab	6	1 (16.7)	1 (16.7)	4 (66.7)
Urine	54	7 (12.9)	11 (20.4)	36 (66.7)
Semen	4	0(0.0)	0 (0.0)	4 (100)
High Vaginal Swab(HVS)	14	0 (0.0)	3 (21.4)	11 (78.6)
Endocervical Swab (ECS)	10	0 (0.0)	8 (80.0)	2 (20.0)
Catheter Tip	2	0(0.0)	0 (0.0)	2 (100)
Wound	7	1 (14.2)	1 (14.2)	5 (71.4)
Total	99 (100)	9 (9.1)	24 (24.2)	66 (66.7)

*VRSA=Vancomycin Resistant *S. aureus*; *VISA= Vancomycin intermediate; *VSSA= Vancomycin Sensitive/susceptible

4. DISCUSSION

Staphylococcus aureus is a major cause of nosocomial infections and poses a substantial threat to human health all over the world. This is owing to the organism's highly developed virulence factors, pathogenicity, and the ability to repeatedly acquire resistance to overcome the obstacles that new drugs present [24]. Even though vancomycin is the antimicrobial agent of choice used to treat staphylococcal infections, especially MRSA, there has been a reported decrease in *S. aureus* susceptibility to the drug, as well as the isolation of intermediate- and resistant strains of the bacteria in many countries around the world. In the absence of proper management and treatment alternatives, MRSA and VRSA have become agents of extraordinary relevance, with the possibility of causing very serious global mortality. Furthermore, VRSA often exhibits multidrug resistance (MDR) against a range of antimicrobial drugs available in the market [25]. Since its first description in 1991, vancomycin resistance in *S. aureus* has been the focus of intensive research and a challenge to the healthcare sector[26].

Our study showed that the *S. aureus* isolates were highly resistant to most of the antibiotics used such as cefotaxime, cefixime, imipenem, Augmentin, azithromycin, erythromycin, and ceftriaxone. *S. aureus* has always been an important pathogen capable of developing resistance to novel antimicrobial drugs. Many variables may contribute to this organism's great antibiotic resistance. Self-medication, the availability and usage of antibiotics without a prescription from a competent professional, unreasonable antibiotic intake, noncompliance with prescriptions, and the sale of counterfeit or substandard medications are all contributory factors [27]. All of these are common in Nigeria.

The prevalence of MRSA in our study was 66.0% (99/150), this is consistent with the reports in some parts of the world such as 60.8% and 72% in Bangladesh [28, 29]. Tefera et al reported a lower prevalence of 45.1% in Ethiopia [7]. MRSA has become a global health concern, as indicated by the high prevalence of antibiotic resistance reported in different nations such as 76% in Lahore, India, 21.5 % in Turkey, 72% in Eritrea, and 77.9% in Iran, [17, 30, 31, 32]. The rising trend of MRSA stresses the need for severe infection control methods such as stringent compliance with hand cleanliness, prevention of antibiotic abuse, and a regular MRSA surveillance program [33].

In our study, the overall prevalence of VRSA in the whole isolates was 6.0% (9/150), This is consistent with the work of Bamigboye et al who reported 1.4% in Osogbo, Southwest Ogeferere, et al who reported VRSA of 4.5% in Benin City South South while Alo et al reported 5.3% in Abakiliki, Southeast all in Nigeria [3, 24, 34]. Saderi et al also reported a lower occurrence of 3.6% in Iran 3.6% [35]. A higher prevalence of 44.5% was also reported in Nigeria by Olufunmiso et al.[26]. However, higher prevalence had been reported in some parts of the world including Pakistan 25% [36], Ethiopia 14.1% [7], and Nepal

21% [37]. The influencing factors responsible for the rate of variance could be different geographical areas, variation in sample size and length of study, source of isolates, methodology, antibiotic policy, and status of infection control. Despite these geographical variances in incidence, these different degrees of resistance to vancomycin have resulted in increasing concern about its efficacy for treatment in MRSA infections [26].

The highest occurrence of VRSA was found among urethral swab isolates at 16.7% (1/6) followed by a wound at 14.2% (1/7). Some researchers have reported catheter tips [24, 36] and some in Urine [26]. The variation could be due to sample size and may also be earlier exposure of this drug to isolates which may have enhanced the development of resistance. There is a significant degree of antibiotic abuse in the study area resulting from self-medication, which is frequently accompanied by poor dosage, inability to comply with treatment, and the availability of antibiotics to customers across the counters with or without prescription [38].

Conclusion

The isolates had a high resistance to most of the antibiotics used in our study. The proportion of MRSA was high. The overall occurrence of VRSA among clinical isolates of *Staphylococcus aureus* was 6.0%. The cautious use of vancomycin and other antimicrobial drugs is recommended. The importance of continual monitoring, screening, and susceptibility testing, cannot be overstated. Antibiotics and other prescription pharmaceuticals should be made available to the public under strict regulations. Efforts should also be targeted towards the development of novel drugs to tackle the problem of multidrug failure.

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

1. Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

REFERENCES

1. Ezeh CK, Eze CN, Dibua MEU, Emencheta SC. A meta-analysis on the prevalence of resistance of *Staphylococcus aureus* to different antibiotics in Nigeria. *Antimicrob Resist Infect Control*. 2023 Apr 25;12(1):40. doi: 10.1186/s13756-023-01243-x.
2. Bamigboye BT, Olowe OA, Taiwo SS. Phenotypic and molecular identification of vancomycin resistance in clinical *Staphylococcus aureus* isolates in Osogbo, Nigeria. *Eur J Microbiol Immunol*. 2018;8:25–30. doi: 10.1556/1886.2018.00003
3. Kejela T, Dekosa F High prevalence of MRSA and VRSA among inpatients of Mettu Karl Referral Hospital, Southwest Ethiopia. *Tropical Medicine and International Health* 2022;27:8: 735-741
4. McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in *Staphylococcus aureus*. *Yale J Biol Med*. 2017;90(2):269–681.
5. Shariati A, Dadashi M, Moghadam MT. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate *Staphylococcus aureus* clinical isolates: a systematic review and meta-analysis. *Sci Rep*. 2020;10:12689. doi: 10.1038/s41598-020-69058-z.
6. Khan A, Wilson B, Gould IM. Current and future treatment options for community-associated MRSA infection. *Expert Opin Pharmacother*. 2018;19 (5):457–470. doi: 10.1080/14656566.2018.1442826.
7. Tefera S, Awoke T, Mekonnen D. Methicillin and Vancomycin Resistant *Staphylococcus aureus* and associated factors from Surgical ward Inpatients at Debre Markos Referral Hospital, Northwest Ethiopia. *Infection and Drug Resistance* 2021; 14: 3053-3062
8. Sompolinsky D, Zaidenzaig Y, Ziegler-Schlomowitz R, Abramova N. Mechanism of tetracycline resistance in *Staphylococcus aureus*. *J Gen Microbiol*. 1970;62(3):351–362. doi: 10.1099/00221287-62-3-351.
9. Li XF, Fan XJ, Guo XJ, Feng P, Lu XJ, Gao YY, et al. A study on the mechanism of drug resistance in *Staphylococcus aureus*. *Sichuan Da Xue Xue Bao Yi Xue Ban*. 2006;37(3):365–368.
10. Yamagishi S, Nakajima Y, Inoue M, Oka Y. Decrease in accumulation of macrolide antibiotics as a mechanism of resistance in *Staphylococcus aureus*. *Jpn J Microbiol*. 1971;15(1):39–52. doi: 10.1111/j.1348-0421.1971.tb00549.x.
11. Tomasz A. The staphylococcal cell wall. In: Vincent A. Fischetti, Richard P. Novick, Joseph J. Ferretti, Daniel A. Portnoy, Julian I. Rood, editors. *Gram-Positive Pathogens*. New York: Wiley Online Library; 2006;443–455. doi: 10.1128/9781555816513.ch36
12. D'Agata EM, Webb GF, Horn MA, Moellering RC, Ruan S. Modeling the invasion of community-acquired methicillin-resistant *Staphylococcus aureus* into hospitals. *Clin Infect Dis*. 2009;48(3):274–284. doi: 10.1086/595844
13. Zhu W, Murray PR, Huskins WC, et al. Dissemination of an Enterococcus Inc18-Like vanA plasmid associated with vancomycin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2010;54(10):4314–4320. doi: 10.1128/AAC.00185-10
14. Selim S, Faried OA, Almuhayawi MS, Saleh FM, Sharaf M, El Nahhas N, Warrad M. Incidence of Vancomycin-Resistant *Staphylococcus aureus* Strains among Patients with Urinary Tract Infections. *Antibiotics (Basel)*. 2022 Mar 18;11(3):408. doi: 10.3390/antibiotics11030408.
15. Friedman N.D., Temkin E., Carmeli Y. The Negative Impact of Antibiotic Resistance. *Clin. Microbiol. Infect*. 2016;22:416–422. doi: 10.1016/j.cmi.2015.12.002.
16. Faron M.L., Ledebor N.A., Buchan B.W. Resistance Mechanisms, Epidemiology, and Approaches to Screening for Vancomycin-Resistant Enterococcus in the Health Care Setting. *J. Clin. Microbiol*. 2016;54:2436–2447. doi: 10.1128/JCM.00211-16.
17. Liaqat F, Sheikh AA, Nazir J, et al. Isolation identification and control of vancomycin resistant *Staphylococcus aureus*. *Pak J Pharm Sci*. 2015;28(3):997–1004.
18. Alani HA, Hassawi DS, Flayih MT. Patterns of antibiotic resistance in *Staphylococcus aureus* isolates and detection the heteroresistance to vancomycin by population analysis method. *JUAPS*. 2017;11(3):26–33.
19. Kateete DP, Kimani CN, Katabazi FA, et al. Identification of *Staphylococcus aureus*: DNase and Mannitol salt agar improve the efficiency of the tube coagulase test. *Ann Clin Microbiol Antimicrob*. 2010; 9: 23

20. Baron EJ, Peterson LR, Tenover FC, Tenover FC, Tenover FC. Baily and Scott's Diagnostic Microbiology 9th Edition; Mosby Inc. St Louis Baltimore; 1994: 362-385
21. Clinical and Laboratory Standards Institute, Document M100-S29. Performance Standards for Antimicrobial Susceptibility Testing. 25th ed, CLSI; 2019.
22. Dhungel S, Rijal KR, Yadav B, Dhungel B, Adhikari N, Shrestha UT et al Methicillin-Resistant *Staphylococcus aureus* (MRSA): Prevalence, Antimicrobial Susceptibility Pattern, and Detection of *mecA* Gene among Cardiac Patients from a Tertiary Care Heart Center in Kathmandu, Nepal. *Infectious Diseases: Research and Treatment*, 2021;14: 1-10
23. Anosike IK, Ebana RUB, Edet UO, Umoh IS. Isolation of vancomycin resistant *Staphylococcus aureus* from the wounds of hospital patients in Uyo, Akwalbom State, Nigeria *World News of Natural Sciences* 2019; 24: 134-144
24. Ogefere HO, Igwe I. Vancomycin resistant *Staphylococcus aureus* from Clinical Isolates in Benin City, Nigeria, *Sokoto Journal of Medical Laboratory Sciences*. 2021; 6 (3):5-10
25. Wu Q, Sabokroo N, Wang Y, Hashemian M, Karamollahi S, Kouhsari E. Systematic review and meta-analysis of the epidemiology of vancomycin-resistance *Staphylococcus aureus* isolates. *Antimicrob Resist Infect Control* .2021; 10:101
26. Olufunmiso O, Tolulope I, Roger C. Multidrug and Vancomycin resistance among clinical isolates of *Staphylococcus aureus* from different Teaching Hospitals in Nigeria. *Afri Health Sci*. 2017; 17(3): 797-807
27. Bale MI, Babatunde SK, Adedayo MR, Ajiboye AE, Ajao AT. Characterization of methicillin-resistant *Staphylococcus aureus* isolates from apparently healthy individuals in Maletete, Kwara State, Nigeria. *African journal of Clinical and Experimental Microbiology* 2019. 20; 1: 17-24
28. Maharajan M, Sah AK, Pyakurel S, Thapa S, Maharjan S, Shrestha UT. Molecular confirmation of Vancomycin-resistant *Staphylococcus aureus* with *van A* gene from Hospital in Kathmandu. *International Journal of Microbiology*. 2021, Article ID 3847347, 8 pages
29. Hasan R, Acharjee M, Noor R. Prevalence of vancomycin resistant *Staphylococcus aureus* (VRSA) in methicillin resistant *S. aureus* (MRSA) strains isolated from burn wound infections. *Tzu Chi Med J*. 2016;28(2):49–53. doi: 10.1016/j.tcmj.2016.03.002
30. Rağbetli C, Parlak M, Bayram Y, Guducuoglu H, Ceylan N. Evaluation of antimicrobial resistance in *Staphylococcus aureus* isolates by years. *InterdiscipPerspect Infect Dis*. 2016;2016. doi: 10.1155/2016/9171395
31. Garoy EY, Gebreab YB, Achila OO, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA): prevalence and antimicrobial sensitivity pattern among patients—a multicenter study in Asmara, Eritrea. *Can J Infect Dis Med Microbiol*. 2019;2019. doi: 10.1155/2019/8321834
32. Emaneini M, Beigverdi R, van Leeuwen WB, et al. Prevalence of methicillin-resistant *Staphylococcus aureus* isolated from burn patients in Iran: a systematic review and meta-analysis. *J Glob Antimicrob Resist*. 2018;12:202–206. doi: 10.1016/j.jgar.2017.10.015
33. Kirti L, Jyoti S, Pratibha M, Sumit L. Prevalence pattern of MRSA from rural medical college of North India: A cause of concern. *Journal of family Medicine and primary care* 2021; 10(2) : 752-757
34. Alo M, Ugah U, Okoro N. Epidemiology of VRSA among clinical isolates in a tertiary hospital in Abakiliki, Nigeria. *American Journal of Epidemiology and infectious Diseases* 2013; 1 (3): 24-26
35. Saderi H, Owlia P, Shahrbanooie R. Vancomycin resistance among the clinical isolates of *Staphylococcus aureus*. *Arch Iran Med*. 2005;8(2):100–103.
36. Siddiqui T, Muhammad IN, Khan MN, Naz S, Bashir L, Sarosh N, Masood R, Ali A et al. MRSA: Prevalence and susceptibility pattern in health care setups of Karachi. *Pakistan Journal of Pharmaceutical Science* 2017; 30: 2417-2421
37. Mimejad R, Fallahi S, Kiani J, Jeddi F, Khoobdel M, Jonaidi N, Alaeddini F. Epidemiology assessment of bacterial agents in osteomyelitis and their antibiotic resistance pattern determination. *J Biol Sci*. 2008;8:478–481.

38. Kumurya AS, Yahaya H. Detection of vancomycin resistance rate among Methicillin-resistant *Staphylococcus aureus* isolates in Kano, Nigeria. *Access Journal of Microbiology* 2016;2 (1):7-12

UNDER PEER REVIEW